Immunome(NASDAQ) IMNM

Immunome, Inc. NASDAQ:IMNM helps doctors treat cancer with targeted medicines. These drugs destroy tumors without hurting healthy cells. The treatments help people fighting rare or advanced cancers.

Targeting Cancer With Precision

• Varegacestat: Oral medicine for desmoid tumors awaiting a federal approval decision by April 2027.
• IM-1021: Antibody-drug conjugate, which pairs an antibody with a drug to target B-cell lymphomas.
• IM-3050: Radioligand therapy designed to deliver radioactive material directly to cancer-associated cells.
• IM-1340: Targeted therapy for lung and prostate tumors currently in early development stages.

Recent Steps Forward

• Acquired the lead drug candidate varegacestat from Ayala Pharmaceuticals in March 2024.
• Submitted a new drug application to the U.S. Food and Drug Administration for varegacestat in April 2026.
• Dosed the first patient in a Phase 1 clinical trial for the IM-1617 program in June 2026.
• Began human testing for the radioactive therapy IM-3050 in its first patient in July 2026.

How the Science Works

Immunome uses specialized technology to build antibody-drug conjugates. These medicines link cancer-killing drugs to targeted antibodies to reach tumors while protecting healthy tissue. The company employs a development team with experience creating multiple approved oncology therapies.

The Financial Scorecard

• Net loss was $73.1 million for the three months ended June 30, 2026.
• Research and development spending reached $59.9 million for the three months ended June 30, 2026.
• Cash and cash equivalents were $217.7 million as of June 30, 2026.
• Marketable securities totaled $302.3 million as of June 30, 2026.
• Market cap was $2.4 billion in Q2 2026, up 196.6% year over year.

Bottom Line

Immunome has grown into a clinical-stage biotechnology company with several active programs for treating tumors. Its focus on targeted delivery methods and late-stage assets drives its current effort to improve cancer care.